Zentalis Pharmaceuticals, Inc. (ZNTL) Operating income 2019–2025
Zentalis Pharmaceuticals, Inc. (ZNTL) annual operating income history from SEC filings — each fiscal year as reported.
-$152.8MFY2025 · since FY2019: -$46.8M → -$152.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$152.8M | +20.1% |
| FY2024 | -$191.2M | +36.2% |
| FY2023 | -$299.5M | -31.8% |
| FY2022 | -$227.3M | -5.0% |
| FY2021 | -$216.5M | -82.3% |
| FY2020 | -$118.8M | -153.6% |
| FY2019 | -$46.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ZNTL financial trends
ZNTL RevenueZNTL Net incomeZNTL Net marginZNTL Gross profitZNTL Gross marginZNTL Operating marginZNTL Operating cash flowZNTL Free cash flowZNTL Capital expendituresZNTL Return on equityZNTL Stock buybacksZNTL Dividends paidZNTL Total assetsZNTL Total liabilitiesZNTL Shareholders’ equityZNTL overview →